Medical Research News

RSS

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

11 Oct 2010

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

11 Oct 2010

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

11 Oct 2010

Fertility concerns of cancer survivors inadequately addressed, study finds

Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.

11 Oct 2010

Sexual issues a major concern for cancer patients taking new targeted drugs

New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient’s sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients.

11 Oct 2010

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

Researchers in Canada and France have raised concerns about substantial inconsistencies in a basic aspect of the way Phase-I and Phase-II cancer clinical trials are designed.

11 Oct 2010

New phase 2 study shows first-line promise of lung cancer drug PF-299

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

$Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer$

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

11 Oct 2010

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Mature results from a landmark Phase-III trial have confirmed that patients with EGFR mutation-positive advanced non-small cell lung cancer have better overall survival when treated with gefitinib or chemotherapy than patients whose tumors do not carry such mutations.

11 Oct 2010

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovarian cancer, primary peritoneal cancer or Fallopian tube cancer.

11 Oct 2010

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

11 Oct 2010

Incentivized structured weight loss program with free prepared meals effectively promotes weight loss

In another article being released early online, Cheryl L. Rock, Ph.D., R.D., from Moores UCSD Cancer Center, La Jolla, Calif., and colleagues, conducted a randomized controlled trial of weight loss and weight maintenance in 442 overweight or obese women (BMI, 25 - 40), ages 18 to 69, over a two year period with follow-up between November 2007 and April 2010.

11 Oct 2010

DATATRAK signs agreement for three new Phase III oncology studies

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of an Enterprise Agreement for three new Phase III oncology studies with an existing client. These multi-center studies will be deployed utilizing the unified DATATRAK eClinical™ platform.

11 Oct 2010

GSU professor receives USDA grant to study dynamics of childhood obesity

A Georgia State University professor has received a U.S. Department of Agriculture grant to look at the obesity trends from childhood to adolescence.

11 Oct 2010

University of Missouri creates National Botanical Research Center with $7.5M NIH grant

Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.

11 Oct 2010

Progress in understanding mechanism behind photocontact allergy

What happens to sunscreens when they are exposed to sunlight? And how is the skin affected by the degradation products that form? This has been the subject of research at the University of Gothenburg and Chalmers University of Technology that will be presented at the upcoming dermatologist conference in Gothenburg.

11 Oct 2010

Research reveals that fragrances can cause contact allergy

The fragrances used in many household and skincare products can cause contact allergy when exposed to oxygen in the air, reveals research from the University of Gothenburg's Faculty of Science in conjunction with the University of Gothenburg to be presented at the dermatologist conference in Gothenburg.

11 Oct 2010

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and was published in Cancer Prevention Research, on October 5, 2010.

11 Oct 2010

Medical Research News

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

Fertility concerns of cancer survivors inadequately addressed, study finds

Sexual issues a major concern for cancer patients taking new targeted drugs

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

New phase 2 study shows first-line promise of lung cancer drug PF-299

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

Incentivized structured weight loss program with free prepared meals effectively promotes weight loss

DATATRAK signs agreement for three new Phase III oncology studies

GSU professor receives USDA grant to study dynamics of childhood obesity

University of Missouri creates National Botanical Research Center with $7.5M NIH grant

Progress in understanding mechanism behind photocontact allergy

Research reveals that fragrances can cause contact allergy

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News